bpc-157 human clinical trial musculoskeletal pain Multifunctionality and Possible Medical Application of the BPC 157 Peptide—Literature and Patent Review Regeneration or Risk? A Narrative
Description
Curr Med Res Opin
The 10 mg/day arm showed a smaller reduction than the 1 mg group, confirming the absence of a dose-dependent response above the threshold range
While the results are promising, a lot of evidence is anecdotal or from animal studies
"I hurt my knee back in 2020
Customized dosing and monitoring are essential to harness the benefits of Ipamorelin and CJC-1295 while minimizing risks
Research is emerging, so a naturopathic doctor can help weigh benefits, sourcing, and safety
